Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection

Sexually Transmitted Infections

Volumn 75, Issue 6, 1999, Pages 398-402

  Patel, R ^a   Tyring, S ^b   Strand, A ^c   Price, M J ^d   Grant, D M ^d  

^a ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d NONE

Author keywords

Genital herpes; Quality of life; Suppressive antiviral therapy

Indexed keywords

ACICLOVIR; PLACEBO; VALACICLOVIR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENITAL HERPES; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

EID: 0033400805     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.75.6.398     Document Type: Article

References (16)

1. 1 Corey L. In: Holmes KK, Mardh PA, Sparling PF, Wiesner PJ, eds. Genital herpes in sexually transmitted diseases. New York: McGraw-Hill Information Services Company, Health Professional Division, 1989.
2. 2 Jeffries D, Barton S, Johnson R, et al. Issues in herpes management. Antiviral Chem Chemother 1994;5:23-9.
3. 3 Goldberg LH, Kaufman RH, Kurtz TO, et al. Continuous five-year treatment of patients with frequently recurring genital herpes simplex virus infection with acyclovir. J Med Virol 1993;(suppl 1):45-50.
4. 4 Wagstaff AJ, Faulds D, Goa KL. Acyclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47:153-205.
5. 5 Carney O, Ross E, Ikkos G, et al. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes. Genitourin Med 1993;69: 457-9.
6. 6 Weller S, Blum SR, Doucette M, et al. Pharmacokinetics of the acyclovir prodrug valaciclovir after single-and multiple-dose administration in normal volunteers. Clin Pharmacol Exp Ther 1993;54:595-605.
7. 7 Patel R, Bodsworth NJ, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin Med 1997;73:105-9.
8. 8 Reitano M, Tyring S, Lang A, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large scale dose range finding study. J Infect Dis 1998;178: 603-10.
9. 9 McKenna SP, Doward LC. Measuring quality of life in recurrent genital herpes. Eur Rev Appl Psychol 1995;45: 289-94.
10. 10 Goldmeier D, Johnson A, Byrne M, et al. Psychological implications of recurrent genital herpes. Genitourin Med 1998;64:327-30.
11. 11 Doward LC, McKenna SP, Kohlmann T, et al. The international development of the RGHQoL: a quality of life measure for recurrent genital herpes. Quality of Life Res 1998;7:143-53.
12. 12 Patel R, Bodsworth NJ, Maclaine GDH, et al. The burden of illness of recurrent genital herpes. Abstract accepted to ICC, 1999.
13. 13 Swanson JM, Chenitz WC. Psychosocial aspects of genital herpes: a review of the literature. Public Health Nursing 1990;7:96-104.
14. 14 Catotti DN, Clarke P, Catoe KE. Herpes revisited: still a cause of concern. Sex Transm Dis 1993;20:77-80.
15. 15 Mindel A, Weller IVD, Faherty A, et al. Prophylactic oral acyclovir in recurrent genital herpes. Lancer 1988;ii:57-9.
16. 16 Kinghorn GR, Jeavons M, Rowland M, et al Acyclovir prophylaxis of recurrent genital herpes: a randomised placebo controlled cross-over study. Genitourin Med 1988; 61:387-30.